T Fujimoto
About
In The Last Decade
T Fujimoto
36 papers receiving 1.4k citations
Hit Papers
Peers
Comparison fields: 5 of 61
- Hematology 1.1k
- Molecular Biology 633
- Public Health, Environmental and Occupational Health 391
- Genetics 370
- Oncology 185
Countries citing papers authored by T Fujimoto
This map shows the geographic impact of T Fujimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T Fujimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T Fujimoto more than expected).
Fields of papers citing papers by T Fujimoto
This network shows the impact of papers produced by T Fujimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T Fujimoto. The network helps show where T Fujimoto may publish in the future.
Co-authorship network of co-authors of T Fujimoto
This figure shows the co-authorship network connecting the top 25 collaborators of T Fujimoto. A scholar is included among the top collaborators of T Fujimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T Fujimoto. T Fujimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 99 | |
| 3 | [Pharmacokinetic studies of all-trans retinoic acid (ATRA) and pilot study of intermittent schedule of ATRA and chemotherapy in childhood acute promyelocytic leukemia. Children's Cancer and Leukemia Study Group]. | 8 |
| 4 | Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. breakdown → | 902 |
| 5 | [Current status in treatment of childhood cancer]. | 1 |
| 6 | Improvement in treatment of childhood acute lymphoblastic leukemia: a 10-year study by the Children's Cancer and Leukemia Study Group. | 10 |
| 7 | [Comparative trial of granisetron versus granisetron plus methylprednisolone for the prevention of nausea and vomiting induced by cancer chemotherapy]. | 3 |
| 8 | [Mediastinal widening simulating relapse in a case of Hodgkin's disease]. | 1 |
| 9 | Multi-institutional study of all-trans-retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukaemia Study Group of the Ministry of Health and Welfare. | 65 |
| 10 | Retrospective analysis of late intensification therapy with high-dose methotrexate for standard-risk acute lymphoblastic leukemia in childhood (CCLSG-S811 study). The Children's Cancer and Leukemia Study Group. | 0 |
| 11 | 5 | |
| 12 | [A prognostic factor in childhood acute lymphoblastic leukemia: implication of cellular DNA contents. Children's Cancer and Leukemia Study Group]. | 0 |
| 13 | [Acute childhood leukemia]. | 1 |
| 14 | 9 | |
| 15 | 1 | |
| 16 | [Treatment of childhood acute lymphoblastic leukemia: efficacy of intermittent pulses of 6-mercaptopurine and methotrexate for maintenance chemotherapy, CCLSG-S811 (phase III study). Children's Cancer and Leukemia Study Group]. | 1 |
| 17 | [Clinical pharmacology of methotrexate (MTX)--altered central nervous system pharmacology of MTX with meningial relapse of childhood leukemia]. | 0 |
| 18 | [Pharmacokinetics of intrathecal chemotherapy and clinical problems]. | 6 |
| 19 | 0 | |
| 20 | [Chemotherapy of acute childhood leukemia. I. Comparison of high dose infusion of MTX as sequential-complementary method for maintenance of remission (author's transl)]. | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.